Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PRGO, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dextromethorphan | Common Cold | Phase 4 · NCT01257542 | Terminated |
| Vivomixx | Breast Cancer | Phase 1/2 · NCT03518268 | Unknown |
Also used in these trials (approved or third-party drugs, not PRGO's own candidates): Pseudoephedrine Hydrochloride, Famotidine, Ibuprofen, Naproxen.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PRGO holds $436.6M in cash and short-term investments (as of Sep 26, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRGO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 20,988,733 | 15.12% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 8,254,465 | 5.95% | 2026-03-31 |
| Neuberger Berman Group LLC | Institution (13G, 5%+) | 7,535,309 | 5.43% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 7,260,072 | 5.23% | 2026-03-31 |
| Patrick Lockwood-Taylor Former CEO and director · +50,458 options |
Insider | 123,170 | 0.09% | 2026-06-05 |
| Eduardo Guarita Bezerra EVP & Chief Financial Officer · +141,376 options |
Insider | 84,700 | 0.06% | 2026-07-08 |
| Geoffrey M. Parker Director |
Insider | 77,127 | 0.06% | 2026-09-11 |
| Robert Willis EVP & CHRO · +60,085 options |
Insider | 50,568 | 0.04% | 2026-07-08 |
| Bradley A Alford Director · +2,059 options |
Insider | 46,121 | 0.03% | 2026-09-11 |
| Donal O'Connor Director |
Insider | 35,633 | 0.03% | 2026-05-13 |
| Albert Manzone Interim President and CEO, Director · +235,627 options |
Insider | 16,353 | 0.01% | 2026-07-08 |
| Roberto Khoury EVP and President of CSCI · +113,101 options |
Insider | 14,113 | 0.01% | 2026-07-08 |
Share count 138,801,872 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRGO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →